Recital 12, Regulation (EU) 2024/2694

In forcesince 17 Oct 2024

The Commission assessed all the information provided by the applicant and considered that it has sufficiently substantiated the fulfilment of the requirements laid down in Article 26(2) of Regulation (EU) 2015/2283. Therefore, the bioavailability study in rats, the in vitro bacterial reverse mutation assay, the in vivo micronucleus test, and the randomised, placebo-controlled human study should be protected in accordance with Article 27(1) of Regulation (EU) 2015/2283. Accordingly, only the applicant should be authorised to place magnesium L-threonate on the market within the Union during a period of five years from the entry into force of this Regulation.